Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Chabanon, R.M. Morel, D. Eychenne, T. Colmet-Daage, L. Bajrami, I. Dorvault, N. Garrido, M. Meisenberg, C. Lamb, A. Ngo, C. Hopkins, S.R. Roumeliotis, T.I. Jouny, S. Hénon, C. Kawai-Kawachi, A. Astier, C. Konde, A. Del Nery, E. Massard, C. Pettitt, S.J. Margueron, R. Choudhary, J.S. Almouzni, G. Soria, J.-. Deutsch, E. Downs, J.A. Lord, C.J. Postel-Vinay, S. (2021). PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer research, Vol.81 (11), pp. 2888-2902.

Zatreanu, D. Robinson, H.M. Alkhatib, O. Boursier, M. Finch, H. Geo, L. Grande, D. Grinkevich, V. Heald, R.A. Langdon, S. Majithiya, J. McWhirter, C. Martin, N.M. Moore, S. Neves, J. Rajendra, E. Ranzani, M. Schaedler, T. Stockley, M. Wiggins, K. Brough, R. Sridhar, S. Gulati, A. Shao, N. Badder, L.M. Novo, D. Knight, E.G. Marlow, R. Haider, S. Callen, E. Hewitt, G. Schimmel, J. Prevo, R. Alli, C. Ferdinand, A. Bell, C. Blencowe, P. Bot, C. Calder, M. Charles, M. Curry, J. Ekwuru, T. Ewings, K. Krajewski, W. MacDonald, E. McCarron, H. Pang, L. Pedder, C. Rigoreau, L. Swarbrick, M. Wheatley, E. Willis, S. Wong, A.C. Nussenzweig, A. Tijsterman, M. Tutt, A. Boulton, S.J. Higgins, G.S. Pettitt, S.J. Smith, G.C. Lord, C.J. (2021). Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nature communications, Vol.12 (1).  show abstract

Khalique, S. Pettitt, S.J. Kelly, G. Tunariu, N. Natrajan, R. Banerjee, S. Lord, C.J. (2020). Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. The journal of pathology: clinical research, Vol.6 (1), pp. 3-11.

Zandarashvili, L. Langelier, M.-. Velagapudi, U.K. Hancock, M.A. Steffen, J.D. Billur, R. Hannan, Z.M. Wicks, A.J. Krastev, D.B. Pettitt, S.J. Lord, C.J. Talele, T.T. Pascal, J.M. Black, B.E. (2020). Structural basis for allosteric PARP-1 retention on DNA breaks. Science, Vol.368 (6486).

Yap, T.A. Kristeleit, R. Michalarea, V. Pettitt, S.J. Lim, J.S. Carreira, S. Roda, D. Miller, R. Riisnaes, R. Miranda, S. Figueiredo, I. Rodrigues, D.N. Ward, S. Matthews, R. Parmar, M. Turner, A. Tunariu, N. Chopra, N. Gevensleben, H. Turner, N.C. Ruddle, R. Raynaud, F.I. Decordova, S. Swales, K.E. Finneran, L. Hall, E. Rugman, P. Lindemann, J.P. Foxley, A. Lord, C.J. Banerji, U. Plummer, R. Basu, B. Lopez, J.S. Drew, Y. de Bono, J.S. (2020). Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers. Cancer discovery, Vol.10 (10), pp. 1528-1543.

Pettitt, S.J. Frankum, J.R. Punta, M. Lise, S. Alexander, J. Chen, Y. Yap, T.A. Haider, S. Tutt, A.N. Lord, C.J. (2020). Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer discovery, Vol.10 (10), pp. 1475-1488.

Pettitt, S.J. Lord, C.J. (2019). Dissecting PARP inhibitor resistance with functional genomics. Current opinion in genetics & development, Vol.54, pp. 55-63.

Chabanon, R.M. Muirhead, G. Krastev, D.B. Adam, J. Morel, D. Garrido, M. Lamb, A. Hénon, C. Dorvault, N. Rouanne, M. Marlow, R. Bajrami, I. Cardeñosa, M.L. Konde, A. Besse, B. Ashworth, A. Pettitt, S.J. Haider, S. Marabelle, A. Tutt, A.N. Soria, J.-. Lord, C.J. Postel-Vinay, S. (2019). PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer. Journal of clinical investigation, Vol.129 (3), pp. 1211-1228.

Lord, C. Guettler, S. Lord, C. Guettler, S. (2018). Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nature communications, Vol.9.  show abstract

Barazas, M. Annunziato, S. Pettitt, S.J. de Krijger, I. Ghezraoui, H. Roobol, S.J. Lutz, C. Frankum, J. Song, F.F. Brough, R. Evers, B. Gogola, E. Bhin, J. van de Ven, M. van Gent, D.C. Jacobs, J.J. Chapman, R. Lord, C.J. Jonkers, J. Rottenberg, S. (2018). The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. Cell reports, Vol.23 (7), pp. 2107-2118.

Krastev, D.B. Pettitt, S.J. Campbell, J. Song, F. Tanos, B.E. Stoynov, S.S. Ashworth, A. Lord, C.J. (2018). Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. Nature communications, Vol.9 (1).

Holme, H. Gulati, A. Brough, R. Fleuren, E.D. Bajrami, I. Campbell, J. Chong, I.Y. Costa-Cabral, S. Elliott, R. Fenton, T. Frankum, J. Jones, S.E. Menon, M. Miller, R. Pemberton, H.N. Postel-Vinay, S. Rafiq, R. Selfe, J.L. von Kriegsheim, A. Munoz, A.G. Rodriguez, J. Shipley, J. van der Graaf, W.T. Williamson, C.T. Ryan, C.J. Pettitt, S. Ashworth, A. Strauss, S.J. Lord, C.J. (2018). Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific reports, Vol.8 (1).

Nikkilä, J. Kumar, R. Campbell, J. Brandsma, I. Pemberton, H.N. Wallberg, F. Nagy, K. Scheer, I. Vertessy, B.G. Serebrenik, A.A. Monni, V. Harris, R.S. Pettitt, S.J. Ashworth, A. Lord, C.J. (2017). Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British journal of cancer, Vol.117 (1), pp. 113-123.

Dréan, A. Williamson, C.T. Brough, R. Brandsma, I. Menon, M. Konde, A. Garcia-Murillas, I. Pemberton, H.N. Frankum, J. Rafiq, R. Badham, N. Campbell, J. Gulati, A. Turner, N.C. Pettitt, S.J. Ashworth, A. Lord, C.J. (2017). Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Molecular cancer therapeutics, Vol.16 (9), pp. 2022-2034.

Pettitt, S.J. Krastev, D.B. Pemberton, H.N. Fontebasso, Y. Frankum, J. Rehman, F.L. Brough, R. Song, F. Bajrami, I. Rafiq, R. Wallberg, F. Kozarewa, I. Fenwick, K. Armisen-Garrido, J. Swain, A. Gulati, A. Campbell, J. Ashworth, A. Lord, C.J. (2017). Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. Scientific data, Vol.4 (1).

Pettitt, S.J. Tan, E.-. Yusa, K. (2015). piggyBac Transposon-Based Insertional Mutagenesis in Mouse Haploid Embryonic Stem Cells. , , pp. 15-28.

Li, M.A. Pettitt, S.J. Eckert, S. Ning, Z. Rice, S. Cadiñanos, J. Yusa, K. Conte, N. Bradley, A. (2013). The piggyBac transposon displays local and distant reintegration preferences and can cause mutations at noncanonical integration sites. Mol cell biol, Vol.33 (7), pp. 1317-1330.  show abstract

Pettitt, S.J. Rehman, F.L. Bajrami, I. Pemberton, H. Brough, R. Kozarewa, I. Lord, C.J. Ashworth, A. (2013). Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity. New technology and bioinformatics, .

Pettitt, S.J. Rehman, F.L. Bajrami, I. Brough, R. Wallberg, F. Kozarewa, I. Fenwick, K. Assiotis, I. Chen, L. Campbell, J. Lord, C.J. Ashworth, A. (2013). A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. Plos one, Vol.8 (4), p. e61520.  show abstract

Huang, Y. Pettitt, S.J. Guo, G. Liu, G. Li, M.A. Yang, F. Bradley, A. (2012). Isolation of homozygous mutant mouse embryonic stem cells using a dual selection system. Nucleic acids research, Vol.40 (3), pp. e21-e21.

Li, M.A. Pettitt, S.J. Yusa, K. Bradley, A. (2010). Genome-Wide Forward Genetic Screens in Mouse ES Cells. , , pp. 217-242.

Pettitt, S.J. Liang, Q. Rairdan, X.Y. Moran, J.L. Prosser, H.M. Beier, D.R. Lloyd, K.C. Bradley, A. Skarnes, W.C. (2009). Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat methods, Vol.6 (7), pp. 493-495.  show abstract

Bajrami, I. Marlow, R. van de Ven, M. Brough, R. Pemberton, H. Frankum, J. Song, F. Raquif, R. Konde, A. Krastev, D. Menon, M. Campbell, J. Gulati, A. Kumar, R. Pettitt, S. Gurden, M. Cardenosa, M. Chong, I. Gazinska, P. Wallberg, F. Sawyer, E. Martin, L. Dowsett, M. Linardopoulos, S. Natrajan, R. Ryan, C. Derksen, P. Jonkers, J. Tutt, A. Ashworth, A. Lord, C. E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer. Cancer discovery, .

Pettitt, S. Lord, C. PARP inhibitors and breast cancer – highlights and hang-ups. Expert review on precision medicine and drug development, .

Noordermeer, S. Adam, S. Setiaputra, D. Barazas, M. Pettitt, S. King, A. Olivieri, M. Alvarez-Quilon, A. Moatti, N. Zimmermann, M. Annunziato, S. Krastev, D. Song, F. Brandsma, I. Frankum, J. Brough, R. Sherker, A. Landry, S. Szilard, R. Munro, M. McEwan, A. Goullet de Rugby, T. Lin, Z. Hart, T. Moffat, J. Gingras, A. Martin, A. Attikum, H. Jonkers, J. Lord, C. Rottenberg, S. Durocher, D. The Shieldin complex mediates 53BP1-dependent DNA repair. Nature, .

Brough, R. Gulati, A. Haider, S. Kumar, R. Campbell, J. Knudsen, E. Pettitt, S. Ryan, C. Lord, C. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene, .

van der Graaf, W. Fleuren, E. ATR is a therapeutic target in synovial sarcoma. Cancer research, .

Chong, I. Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. , .

Carreira, S. Porta, N. Arce-Gallego, S. Seed, G. Llop-Guevara, A. Bianchini, D. Rescigno, P. Paschalis, A. Bertan, C. Baker, C. Goodall, J. Miranda, S. Riisnaes, R. Figueiredo, I. Ferreira, A. Pereira, R. Crespo, M. Gurel, B. Nava Rodrigues, D. Pettitt, S.J. Yuan, W. Serra, V. Rekowski, J. Lord, C.J. Hall, E. Mateo, J. de Bono, J.S. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer discovery, .

In this section

Publications